Codex DNA

SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November…

SAN DIEGO, 19 sept. 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ : DNAY), pionnière des systèmes de biologie synthétique automatisés, a annoncé aujourd'hui le lancement commercial et la première expédition du système BioXp™ 9600, une…

SAN DIEGO, Kalifornien (USA), Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), ein Pionier auf dem Gebiet der automatisierten Tischgerätsysteme für die synthetische Biologie, hat heute die Markteinführung und erste…

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker presentation for the World Vaccine Congress Washington 2022, which is…

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced details for its first Investor R&D Webinar. Management will describe the future…

SAN DIEGO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of a new full-length synthetic genome of the SARS-CoV-2 virus for the…

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present…

SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY) today announced the closing of its initial public offering of 7,666,664 shares of common stock, including the full exercise of the underwriters’ option to…